[{"id":"500cdb1b-cc26-4d01-947d-9f667ab8c48a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771572","created_at":"2021-02-25T15:52:22.502Z","updated_at":"2024-07-02T16:35:07.720Z","phase":"Phase 1","brief_title":"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.","source_id_and_acronym":"NCT04771572","lead_sponsor":"Newave Pharmaceutical Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LP-118"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-24"},{"id":"6b450ba8-fa67-4a5f-912d-deea4c078553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05025358","created_at":"2021-08-27T12:53:06.976Z","updated_at":"2024-07-02T16:36:02.645Z","phase":"Phase 1","brief_title":"A Study of LP-118 in Patients With Advanced Tumors","source_id_and_acronym":"NCT05025358","lead_sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LP-118"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-10-11"}]